

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road
Notting Hill VIC 3168
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au*For Immediate Release*

Melbourne, Australia — 26 October 2012

Nabi to implement a share consolidation

Biota Holdings Limited (ASX:BTA) announces that the board of Nabi Biopharmaceuticals (**Nabi**) has approved a share consolidation, which will take effect on 8 November 2012, whereby every six(6) Nabi shares will be consolidated into a single Nabi share.

As a result, on the implementation of the merger between Biota and Nabi, Biota shareholders will receive 0.1249630125 of a share in the merged group, Biota Pharmaceuticals, Inc., for each Biota share held by them on the record date, being 6 November 2012.

As announced to the ASX on 19 October 2012, immediately after the implementation of the merger, Biota shareholders and Nabi shareholders will hold approximately 83% and 17% respectively of Biota Pharmaceuticals, Inc. The share consolidation will not impact this ownership percentage.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has a well advanced program for human rhinovirus (HRV) infection with a completed Phase IIb study in asthmatic subjects.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product Inavir[®], is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza[™] is a registered trademark of the GlaxoSmithKline group of companies.

Inavir[®] is registered to Daiichi Sankyo.

Further information**Investor/Analyst Enquiries****Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

Shareholder Enquiries

Biota Shareholder Information Line

T: 1300 306 230 (within Australia)

T: +61 2 8280 7169 (International)

Between 8.30am and 7.30pm

(Melbourne time)

Media Enquiries

Nerida Mossop, Hinton & Associates

T: +61 3 9600 1979 / M: +61 437 361 433

Felicity Williams, Hinton & Associates

T: +61 3 9600 1979 / M: +61 416 770 012

US Enquiries

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749